T cell therapy is a rapidly growing form of cancer treatment and many pharmaceutical companies are developing these therapies, all of which are still in the clinical trial stage. Despite positive results, a major problem called cross-reactivity is affecting the industry. In some cases, patients have died as a result of this cross-reactive side effect. As a service provider to pharmaceutical companies Structured Immunity has the patent pending technology to solve the problem of cross-reactivity.

2017  Finalist